Contact
searchSearch
HMP Global

Advertisement

ADVERTISEMENT

Volume 11 - Issue 2 - February 2014

Insights

Interview
Results of the PEARL Registry on Mechanical Thrombectomy of Hemodialysis Fistulas and Grafts: An Interview With Eugene J. Simoni, MD
02/05/2014
At the 2013 VEITHsymposium, Vascular Disease Management spoke with Eugene J. Simoni, MD, about results of the PEARL registry, which studied hemodialysis patients treated with mechanical thrombectomy.
At the 2013 VEITHsymposium, Vascular Disease Management spoke with Eugene J. Simoni, MD, about results of the PEARL registry, which studied hemodialysis patients treated with mechanical thrombectomy.
At the 2013 VEITHsymposium,...
02/05/2014
Vascular Disease Management

Feature

Case Report
A Technique for Enhanced Distal Embolic Protection in the Endovascular Treatment of Iliofemoral Thrombosis With the Trellis Device
02/05/2014
The authors propose a novel technique of enhanced embolic protection that combines use of the Trellis-6 with the SpiderFX Embolic Protection Device (Covidien) to mitigate poor outcomes.
The authors propose a novel technique of enhanced embolic protection that combines use of the Trellis-6 with the SpiderFX Embolic Protection Device (Covidien) to mitigate poor outcomes.
The authors propose a novel...
02/05/2014
Vascular Disease Management
Original Research
Procedural Outcomes of Orbital Atherectomy Treatment of Peripheral Arterial Disease in an Outpatient Office-Based vs Hospital Setting
02/05/2014
The authors analyzed the CONFIRM registry of patients with peripheral arterial disease who were treated with orbital atherectomy in both the office-based and hospital settings and found that orbital atherectomy in an office-based setting was...
The authors analyzed the CONFIRM registry of patients with peripheral arterial disease who were treated with orbital atherectomy in both the office-based and hospital settings and found that orbital atherectomy in an office-based setting was...
The authors analyzed the CONFIRM...
02/05/2014
Vascular Disease Management
Clinical Images
Recurrent Myocardial Infarctions in a Young Female With Fibromuscular Dysplasia
02/05/2014
The authors present a case of a 49-year-old female with systemic fibromuscular dysplasia who presented with recurrent non-ST-segment elevation myocardial infarctions.
The authors present a case of a 49-year-old female with systemic fibromuscular dysplasia who presented with recurrent non-ST-segment elevation myocardial infarctions.
The authors present a case of a...
02/05/2014
Vascular Disease Management

Department

Letters to the Editor
Next Steps to Collecting More Data for Peripheral Vascular Patients: A Continued Discussion Regarding Rigorous Scientific Data
02/05/2014
Future well-designed and executed randomized control trials that track clinically relevant outcomes, including the cost of the endovascular treatments and long-term outcomes, will enable physicians to determine the optimal therapies for...
Future well-designed and executed randomized control trials that track clinically relevant outcomes, including the cost of the endovascular treatments and long-term outcomes, will enable physicians to determine the optimal therapies for...
Future well-designed and...
02/05/2014
Vascular Disease Management

Column

Clinical Editor's Corner
Distal Protection in Peripheral Vascular Interventions
02/05/2014
Meticulous technique is imperative in all interventions but is particularly important in atherectomy.
Meticulous technique is imperative in all interventions but is particularly important in atherectomy.
Meticulous technique is...
02/05/2014
Vascular Disease Management

Advertisement

Advertisement

Stay in the Know

Vascular Disease Management Newsletter

Advertisement

Advertisement

News

First Aid guidelines
AHA/American Red Cross: Updated First Aid Guidelines Enhance Care for Opioid Overdose, Bleeding, Other Emergencies
11/14/2024
These are the first major comprehensive updates to the first aid guidelines since 2010 and address shifts in how the public manages common and critical first aid emergencies.
These are the first major comprehensive updates to the first aid guidelines since 2010 and address shifts in how the public manages common and critical first aid emergencies.
These are the first major...
11/14/2024
Cath Lab Digest
Late-Breaking Trials
Final Round of Late-Breaking Clinical Trial Results Announced at VIVA24
11/06/2024
The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results for the final round of Late-Breaking Clinical Trials presented at...
The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results for the final round of Late-Breaking Clinical Trials presented at...
The VIVA Foundation, a...
11/06/2024
Vascular Disease Management
Late-Breaking Trials
Third Round of Late-Breaking Clinical Trial Results Announced at VIVA24
11/05/2024
The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results for the third of four rounds of Late-Breaking Clinical Trials...
The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results for the third of four rounds of Late-Breaking Clinical Trials...
The VIVA Foundation, a...
11/05/2024
Vascular Disease Management
Late-Breaking Trials
Second Round of Late-Breaking Clinical Trial Results Announced at VIVA24
11/04/2024
The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results for the second of four rounds of Late-Breaking Clinical Trials...
The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results for the second of four rounds of Late-Breaking Clinical Trials...
The VIVA Foundation, a...
11/04/2024
Vascular Disease Management
Late-Breaking Trials
First Round of Late-Breaking Clinical Trial Results Announced at VIVA24
11/04/2024
The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results for the first of four rounds of Late-Breaking Clinical Trials...
The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results for the first of four rounds of Late-Breaking Clinical Trials...
The VIVA Foundation, a...
11/04/2024
Vascular Disease Management
Image-Guided Therapy
Philips Enrolls First Patient in U.S. Clinical Trial for Innovative Integrated Single-Device to Treat Peripheral Artery Disease
11/04/2024
With a unique world-first ability to perform laser atherectomy and laser-based intravascular lithotripsy using a single device, Philips takes a major step forward in the treatment of peripheral artery disease (PAD) Cardiovascular...
With a unique world-first ability to perform laser atherectomy and laser-based intravascular lithotripsy using a single device, Philips takes a major step forward in the treatment of peripheral artery disease (PAD) Cardiovascular...
With a unique world-first...
11/04/2024
Vascular Disease Management
Pulmonary Embolism
Akura Medical Secures FDA Approval for US Pivotal Trial in Pulmonary Embolism
11/04/2024
QUADRA-PE study will evaluate the safety and effectiveness of the Katana™ Thrombectomy System LOS GATOS, Calif., Nov. 4, 2024 /PRNewswire/ -- Akura Medical, a Shifamed portfolio company focused on reshaping the...
QUADRA-PE study will evaluate the safety and effectiveness of the Katana™ Thrombectomy System LOS GATOS, Calif., Nov. 4, 2024 /PRNewswire/ -- Akura Medical, a Shifamed portfolio company focused on reshaping the...
QUADRA-PE study will evaluate...
11/04/2024
Vascular Disease Management
Peripheral Arterial Disease
FDA Grants R3 Vascular IDE Approval for ELITE-BTK Pivotal Trial of its MAGNITUDE® Drug Eluting Next Generation Bioresorbable Scaffold for Below-the-Knee Peripheral Arterial Disease
11/04/2024
MOUNTAIN VIEW, Calif. – November 4, 2024 – R3 Vascular Inc., a medical device company dedicated to developing and providing novel, best-in-class bioresorbable scaffolds for treating peripheral arterial disease (PAD), is pleased to announce...
MOUNTAIN VIEW, Calif. – November 4, 2024 – R3 Vascular Inc., a medical device company dedicated to developing and providing novel, best-in-class bioresorbable scaffolds for treating peripheral arterial disease (PAD), is pleased to announce...
MOUNTAIN VIEW, Calif. – November...
11/04/2024
Vascular Disease Management
Patient Awareness
Baby Boomers Beware: More Americans Than Ever Before Now at Higher Risk for Common Blood Vessel Diseases
10/31/2024
New survey reveals nearly one in three Americans at highest risk for blood vessel diseases and life-threatening complications report low awareness Society for Vascular Surgery launches the Highway to Health campaign to help people maintain...
New survey reveals nearly one in three Americans at highest risk for blood vessel diseases and life-threatening complications report low awareness Society for Vascular Surgery launches the Highway to Health campaign to help people maintain...
New survey reveals nearly one in...
10/31/2024
Vascular Disease Management
DCB
SIRONA Trial @TCT – First Head-to-Head Comparison of Sirolimus Versus Paclitaxel DCBs in the Treatment of PAD: Sirolimus-Coated Balloons Yield Similar Results to Paclitaxel-Coated Balloons in the Femoropopliteal Artery
10/30/2024
Data from the prospective, multicenter, investigator-initiated SIRONA randomized clinical trial demonstrated MagicTouch™️ sirolimus-coated balloons to be noninferior compared to paclitaxel-coated balloons with regards to the primary safety...
Data from the prospective, multicenter, investigator-initiated SIRONA randomized clinical trial demonstrated MagicTouch™️ sirolimus-coated balloons to be noninferior compared to paclitaxel-coated balloons with regards to the primary safety...
Data from the prospective,...
10/30/2024
Cath Lab Digest

Advertisement

Advertisement

February 2014 Volume 11 Issue 2

View Issue Archive
Editorial Correspondence

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use

Advertisement

Advertisement